Annual Report

Overview

The report records the Nippon Shinyaku Group's third consecutive annual increases in net sales, operating income, ordinary income and net income, with net sales of ¥79,991 million for the year ended March 31, 2015. It highlights new launches including Zalutia and Opsumit and continued development of selexipag for pulmonary arterial hypertension. At its specified main business locations, the company reports FY2014 energy consumption 15.7% below FY1990 and CO2 emissions 3.7% below FY1990. The report also describes CSR initiatives spanning patient and community engagement, employees and environmental management.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2014-2015
Period: 1 April 2014 – 31 March 2015
Language: English
Pages
File size
Restatement: Disclosed

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services